Dynavax Technologies Corp at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
All right. Good afternoon, everyone, and thanks for joining us for today's fireside chat with Dynavax. I'm Evan Wang, a member of the Guggenheim biopharma team. I'm joined by Dynavax's Ryan Spencer, CEO; and Kelly MacDonald, CFO. Let me turn it over to Ryan quickly to start with a brief overview of Dynavax's pipeline, and then we'll jump into Q&A.
Great. Thanks, Evan. I'm going to share some slides here just to help facilitate the overview. So bear with me one second while I get this set up. Okay, thank you. So first, let's just start with a brief mention of our forward-looking statements. And we encourage you to review these as well as the risk factors on our most recent SEC filings.
So a quick overview for Dynavax. I think what you really need to understand right now is the Company is being built around two highly valuable assets, the first being HEPLISAV-B, which is our adult hepatitis B vaccine. And that vaccine is adjuvanted with CpG 1018,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |